INNPF OTC
INNOCAN PHARMA Corp
1W: -20.0%
1M: -5.4%
3M: -68.2%
YTD: -80.6%
1Y: -80.8%
3Y: -88.5%
5Y: -94.7%
$1.40
-0.22 (-13.58%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$29M
+115.5% ▲
Gross Profit
$26M
+118.6% ▲
Operating Income
-$1M
-132.8% ▼
Net Income
-$2M
+61.0% ▲
EPS (Diluted)
$-0.42
+64.7% ▲
EBITDA
-$1M
+67.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $8K | $196K | $3M | $14M | $29M |
| YoY Growth | +0.0% | +2350.0% | +1205.6% | +433.7% | +115.5% |
| Cost of Revenue | $5K | $75K | $452K | $2M | $3M |
| Gross Profit | $3K | $121K | $2M | $12M | $26M |
| Gross Margin | 37.5% | 61.7% | 82.3% | 87.7% | 89.0% |
| R&D Expenses | $1M | $1M | $2M | $2M | $2M |
| SG&A Expenses | $3M | $6M | $7M | $14M | $26M |
| Operating Expenses | $5M | $8M | $8M | $8M | $27M |
| Operating Income | -$5M | -$7M | -$6M | $4M | -$1M |
| Operating Margin | -59062.5% | -3816.3% | -244.9% | 27.8% | -4.2% |
| Interest Expense | $8K | $13K | $2K | $0 | $7K |
| Income Before Tax | -$10M | -$10M | -$4M | -$4M | $919K |
| Tax Expense | $0 | $0 | $1K | $214K | $1M |
| Net Income | -$10M | -$10M | -$4M | -$5M | -$2M |
| Net Margin | -124412.5% | -5126.0% | -147.1% | -34.4% | -6.2% |
| EPS (Diluted) | $-3.99 | $-2.91 | $-0.98 | $-1.19 | $-0.42 |
| EBITDA | -$5M | -$7M | -$4M | -$4M | -$1M |
| Shares Outstanding | 2M | 3M | 4M | 4M | 4M |